Development of Bowman-Birk Inhibitor for chemoprevention of oral head and neck cancer

Annals of the New York Academy of Sciences

Volumn 952, Issue , 2001, Pages 116-123

  Meyskens Jr , Frank L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bowman Birk inhibitor; Oral head and neck cancer; Oral leukoplakia

Indexed keywords

BBI CONCENTRATE; BOWMAN BIRK INHIBITOR; NEU DIFFERENTIATION FACTOR; PROTEINASE INHIBITOR;

CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG INDUCED DISEASE; ENZYME ACTIVITY; HAMSTER; HEAD AND NECK CANCER; HUMAN; LEUKOPLAKIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRECANCER; RANDOMIZED CONTROLLED TRIAL; SOYBEAN;

ANIMALIA; CRICETINAE; GLYCINE MAX;

EID: 0035680564     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb02732.x     Document Type: Conference Paper

References (11)

1. Chemopreventive agents: Protease inhibitors
2. Scission of soybean Bowman-Birk proteinase inhibitor into two small fragments having either trypsin or chymotrypsin inhibitor activity
3. Bowman-Birk soybean protease inhibitor as an anticarcinogen
4. Preparation and production of a cancer chemopreventive agent. Bowman-Birk concentrate
5. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia
6. Predicting cancer development in oral leukoplakia: Ten years of translational research
7. Biomarker intermediate endpoints and cancer prevention
8. Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis
9. The c-erbB-2 protein in oncogenesis: Molecular structure to molecular epidemiology
10. Relationship between protease activity and Neu oncogene expression in patients with oral leukoplakia treated with the Bowman-Birk inhibitor
11. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a Phase IIa chemoprevention trial